HALO · NASDAQ · Biotechnology

Halozyme Therapeutics (HALO)

Enables subcutaneous delivery of partner medicines through ENHANZE technology.

$112.20
vs last close−2.93 (−2.54%)
  1. HALO Stock Rises 36% in a Month: Here's What You Should Know

    Zacks Investment ResearchMarket move